Neuropeptide Y

Product #

Description

Biochem/physiol Actions

Add to Cart

SML0891 L-152,804 ≥98% (HPLC) L-152,804 is a potent and selective non-peptide neuropeptide Y Y5 receptor antagonist. L-152,804 induces a potent reduction of food intake in rodents.
B174 BIBP 3226 Selective non-peptide neuropeptide Y1 (NPY1) receptor antagonist.
B5063 BMS-193885 ≥98% (HPLC) BMS-193885 is a potent, selective Y1 antagonist that is active in both acute and chronic animal models of food intake. Although it is active in vivo, it is not orally bioavailable due to poor intestinal absorption, so it is not being pursued for pharmaceutical development. BMS-193885 has been used as a pre-clinical proof of concept tool for showing efficacy of Y1 antagonism in treating obesity.
SML0855 GW438014A ≥98% (HPLC) GW438014A is a potent and selective neuropeptide Y Y5 receptor antagonist. GW438014A induces a potent reduction of food intake in rodents.
N9398 N-Acetyl-[Leu28, Leu31]-Neuropeptide Y Fragment 24-36 ≥98% (HPLC), powder N-Acetyl-[Leu28, Leu31]-Neuropeptide Y Fragment 24-36 is a neuropeptide Y-Y2 receptor agonist.
Selective neuropeptide Y-Y2 receptor agonist.
P4488 Pancreatic Polypeptide Fragment 1-17–[Ala31, α-Aminoisobutyryl32]-Neuropeptide Y Fragment 18-36 ≥95% (HPLC), solid Selective agonist of the neuropeptide Y receptor.
N5017 Neuropeptide Y human ≥95% (HPLC), powder, synthetic Neuropeptide Y (NPY) plays a vital role in various processes including feeding behaviour, anxiety, epilepsy, circadian, as well as rhythm memory processing, sleep, pain and drug addiction. In addition, it is also implicated in regulation of appetite, body weight and obesity. It controls central endocrine secretion and has potent vasoactive effects on the cardiovascular system. NPY is involved in the pathogenesis of atherosclerosis and coronary artery disease. NPY exhibits antimicrobial activity against Cryptococcus neoformans, Candida albicans and Arthroderma simii.
Vasoconstrictor; brain peptide that inhibits Ca2+-activated K+ channels in vascular smooth muscle. Implicated in the control of blood pressure, sexual behavior and food intake. Inhibits cholecystokinin- and secretin-stimulated pancreatic secretion.
N3266 Neuropeptide Y porcine ≥97% (HPLC), synthetic Vasoconstrictor; brain peptide that inhibits Ca2+-activated K+ channels in vascular smooth muscle. Implicated in the control of blood pressure, sexual behavior and food intake. Inhibits cholecystokinin- and secretin-stimulated pancreatic secretion.
N9407 Neuropeptide Y Fragment 3-36 human, rat ≥95% (HPLC) Endogenous neuropeptide that selectively binds to Y<SUB>2</SUB> and Y<SUB>5</SUB> receptors.
Neuropeptide Y (NPY) plays a vital role in various processes like feeding behavior, anxiety, epilepsy, circadian rhythm, sleep, pain and drug addiction. It also modulates appetite, body weight and obesity. The protein has potent vasoactive effects on the cardiovascular system and controls central endocrine secretion. NPY is involved in the pathogenesis of atherosclerosis and coronary artery disease.

N1272 Neuropeptide Y Fragment 18-36 human, porcine A competitive NPY antagonist in cardiac membranes
N6521 Neuropeptide Y Fragment 13-36 porcine ≥97% (HPLC) Selective neuropeptide Y2 receptor agonist.
N5771 [O-Methyl-Tyr21]-Neuropeptide Y human ≥97% (HPLC) [O-Methyl-Tyr21]-Neuropeptide Y human is a Neuropeptide Y analog with a high affinity for brain receptors.
P4118 [CPP1-7, NPY19-23, Ala31, Aib32, Gln34]-Pancreatic polypeptide First potent and selective Y5 neuropeptide Y receptor agonist.
S6701 SF-11 ≥98% (HPLC) Radioligand studies reveal that SF-11 also targets 5-HT2B and dopamine transporter.1
SF-11 is a potent, selective NPY Y2 receptor antagonist; brain-penetrant.
S5076 SF-22 ≥98% (HPLC) Radioligand studies reveal that SF-22 also targets 5-HT2B and 5-HT6 serotonin receptors and dopamine transporter.1
SF-22 is a potent, selective NPY Y2 receptor antagonist; highly brain-penetrant